International Clinical Trial: A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Single and Multiple Doses of ALT001 in Healthy Chinese Subjects

Geneva, Feb. 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119043) titled 'A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Single and Multiple Doses of ALT001 in Healthy Chinese Subjects' on Feb. 14.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Beijing Tiantan Hospital, Capital Medical University

Condition: Ischemic Stroke

Intervention: Experimental group:Single dose: ALT001 will be administered intravenously once on Day 1. Multiple doses: ALT001 will be administered intravenously once daily from Day 1 for 14 consecutive days.

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrol...